Frontiers in Immunology (Oct 2024)
Peripheral immune profiling of soft tissue sarcoma: perspectives for disease monitoring
- Jani Sofia Almeida,
- Jani Sofia Almeida,
- Jani Sofia Almeida,
- Jani Sofia Almeida,
- Jani Sofia Almeida,
- Jani Sofia Almeida,
- Luana Madalena Sousa,
- Luana Madalena Sousa,
- Luana Madalena Sousa,
- Patrícia Couceiro,
- Patrícia Couceiro,
- Patrícia Couceiro,
- Patrícia Couceiro,
- Patrícia Couceiro,
- Tânia Fortes Andrade,
- Vera Alves,
- Vera Alves,
- Vera Alves,
- Vera Alves,
- Vera Alves,
- António Martinho,
- Joana Rodrigues,
- Joana Rodrigues,
- Ruben Fonseca,
- Ruben Fonseca,
- Paulo Freitas-Tavares,
- Paulo Freitas-Tavares,
- Manuel Santos-Rosa,
- Manuel Santos-Rosa,
- Manuel Santos-Rosa,
- Manuel Santos-Rosa,
- Manuel Santos-Rosa,
- José Manuel Casanova,
- José Manuel Casanova,
- José Manuel Casanova,
- José Manuel Casanova,
- José Manuel Casanova,
- Paulo Rodrigues-Santos,
- Paulo Rodrigues-Santos,
- Paulo Rodrigues-Santos,
- Paulo Rodrigues-Santos,
- Paulo Rodrigues-Santos,
- Paulo Rodrigues-Santos
Affiliations
- Jani Sofia Almeida
- Center for Neurosciences and Cell Biology (CNC), Laboratory of Immunology and Oncology, University of Coimbra, Coimbra, Portugal
- Jani Sofia Almeida
- Faculty of Medicine (FMUC), Institute of Immunology, University of Coimbra, Coimbra, Portugal
- Jani Sofia Almeida
- Center for Investigation in Environment, Genetics and Oncobiology (CIMAGO), University of Coimbra, Coimbra, Portugal
- Jani Sofia Almeida
- Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
- Jani Sofia Almeida
- Center for Innovation in Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Jani Sofia Almeida
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- Luana Madalena Sousa
- Center for Neurosciences and Cell Biology (CNC), Laboratory of Immunology and Oncology, University of Coimbra, Coimbra, Portugal
- Luana Madalena Sousa
- Center for Innovation in Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Luana Madalena Sousa
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- Patrícia Couceiro
- Center for Neurosciences and Cell Biology (CNC), Laboratory of Immunology and Oncology, University of Coimbra, Coimbra, Portugal
- Patrícia Couceiro
- Center for Investigation in Environment, Genetics and Oncobiology (CIMAGO), University of Coimbra, Coimbra, Portugal
- Patrícia Couceiro
- Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
- Patrícia Couceiro
- Center for Innovation in Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Patrícia Couceiro
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- Tânia Fortes Andrade
- Center for Neurosciences and Cell Biology (CNC), Laboratory of Immunology and Oncology, University of Coimbra, Coimbra, Portugal
- Vera Alves
- Faculty of Medicine (FMUC), Institute of Immunology, University of Coimbra, Coimbra, Portugal
- Vera Alves
- Center for Investigation in Environment, Genetics and Oncobiology (CIMAGO), University of Coimbra, Coimbra, Portugal
- Vera Alves
- Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
- Vera Alves
- Center for Innovation in Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Vera Alves
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- António Martinho
- Portuguese Institute for Blood and Transplantation (IPST), Blood and Transplantation Center of Coimbra, Coimbra, Portugal
- Joana Rodrigues
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- Joana Rodrigues
- Tumor Unit of the Locomotor Apparatus, University Clinic of Orthopedics, Orthopedics Oncology Service, Coimbra Hospital and Universitary Centre (CHUC), Coimbra, Portugal
- Ruben Fonseca
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- Ruben Fonseca
- Tumor Unit of the Locomotor Apparatus, University Clinic of Orthopedics, Orthopedics Oncology Service, Coimbra Hospital and Universitary Centre (CHUC), Coimbra, Portugal
- Paulo Freitas-Tavares
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- Paulo Freitas-Tavares
- Tumor Unit of the Locomotor Apparatus, University Clinic of Orthopedics, Orthopedics Oncology Service, Coimbra Hospital and Universitary Centre (CHUC), Coimbra, Portugal
- Manuel Santos-Rosa
- Faculty of Medicine (FMUC), Institute of Immunology, University of Coimbra, Coimbra, Portugal
- Manuel Santos-Rosa
- Center for Investigation in Environment, Genetics and Oncobiology (CIMAGO), University of Coimbra, Coimbra, Portugal
- Manuel Santos-Rosa
- Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
- Manuel Santos-Rosa
- Center for Innovation in Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Manuel Santos-Rosa
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- José Manuel Casanova
- Center for Investigation in Environment, Genetics and Oncobiology (CIMAGO), University of Coimbra, Coimbra, Portugal
- José Manuel Casanova
- Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
- José Manuel Casanova
- Center for Innovation in Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- José Manuel Casanova
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- José Manuel Casanova
- Tumor Unit of the Locomotor Apparatus, University Clinic of Orthopedics, Orthopedics Oncology Service, Coimbra Hospital and Universitary Centre (CHUC), Coimbra, Portugal
- Paulo Rodrigues-Santos
- Center for Neurosciences and Cell Biology (CNC), Laboratory of Immunology and Oncology, University of Coimbra, Coimbra, Portugal
- Paulo Rodrigues-Santos
- Faculty of Medicine (FMUC), Institute of Immunology, University of Coimbra, Coimbra, Portugal
- Paulo Rodrigues-Santos
- Center for Investigation in Environment, Genetics and Oncobiology (CIMAGO), University of Coimbra, Coimbra, Portugal
- Paulo Rodrigues-Santos
- Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
- Paulo Rodrigues-Santos
- Center for Innovation in Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal
- Paulo Rodrigues-Santos
- Clinical and Academic Centre of Coimbra (CACC), Coimbra, Portugal
- DOI
- https://doi.org/10.3389/fimmu.2024.1391840
- Journal volume & issue
-
Vol. 15
Abstract
Studying the tumor microenvironment and surrounding lymph nodes is the main focus of current immunological research on soft tissue sarcomas (STS). However, due to the restricted opportunity to examine tumor samples, alternative approaches are required to evaluate immune responses in non-surgical patients. Therefore, the purpose of this study was to evaluate the peripheral immune profile of STS patients, characterize patients accordingly and explore the impact of peripheral immunotypes on patient survival. Blood samples were collected from 55 STS patients and age-matched healthy donors (HD) controls. Deep immunophenotyping and gene expression analysis of whole blood was analyzed using multiparametric flow cytometry and real-time RT-qPCR, respectively. Using xMAP technology, proteomic analysis was also carried out on plasma samples. Unsupervised clustering analysis was used to classify patients based on their immune profiles to further analyze the impact of peripheral immunotypes on patient survival. Significant differences were found between STS patients and HD controls. It was found a contraction of B cells and CD4 T cells compartment, along with decreased expression levels of ICOSLG and CD40LG; a major contribution of suppressor factors, as increased frequency of M-MDSC and memory Tregs, increased expression levels of ARG1, and increased plasma levels of IL-10, soluble VISTA and soluble TIMD-4; and a compromised cytotoxic potential associated with NK and CD8 T cells, namely decreased frequency of CD56dim NK cells, and decreased levels of PRF1, GZMB, and KLRK1. In addition, the patients were classified into three peripheral immunotype groups: "immune-high," "immune-intermediate," and "immune-low." Furthermore, it was found a correlation between these immunotypes and patient survival. Patients classified as "immune-high" exhibited higher levels of immune-related factors linked to cytotoxic/effector activity and longer survival times, whereas patients classified as "immune-low" displayed higher levels of immune factors associated with immunosuppression and shorter survival times. In conclusion, it can be suggested that STS patients have a compromised systemic immunity, and the correlation between immunotypes and survival emphasizes the importance of studying peripheral blood samples in STS. Assessing the peripheral immune response holds promise as a useful method for monitoring and forecasting outcomes in STS.
Keywords